Acceptable Outcomes of a Progestin-Only Pill in Teens

This POP was associated with less dysmenorrhea and more predictable (and lighter) bleeding with use.

In 2019, Slynd, a new contraceptive progestin-only pill (POP; 24 4-mg drospirenone tablets and 4 inert tablets per pack) received FDA approval (NEJM JW Womens Health Aug 2019; multiple citations). To assess this POP's performance in teens, European researchers conducted an open-label, multicenter manufacturer-sponsored 6-cycle trial with a 7-cycle extension phase. Among 102 participants (age range, 12–17; median age, 16; 99% white), 87% completed 6 cycles and 72% completed 13 cycles.

Among participants reporting dysmenorrhea at baseline, the proportion continuing to experience this symptom decreased with time; in addition, the proportion of participants with scheduled bleeding or spotting (i.e., during the 4 hormone-free days) fell from 50% …

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Acceptable Outcomes of a Progestin-Only Pill in Teens

Topics

Reviewing Author